172 related articles for article (PubMed ID: 38878155)
21. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
23. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
24. Stroke and Fabry Disease: A Review of Literature.
Mishra V; Banerjee A; Gandhi AB; Kaleem I; Alexander J; Hisbulla M; Kannichamy V; Valaiyaduppu Subas S; Hamid P
Cureus; 2020 Dec; 12(12):e12083. PubMed ID: 33489501
[TBL] [Abstract][Full Text] [Related]
25. Innate and Adaptive Immune Response in Fabry Disease.
Mauhin W; Lidove O; Masat E; Mingozzi F; Mariampillai K; Ziza JM; Benveniste O
JIMD Rep; 2015; 22():1-10. PubMed ID: 25690728
[TBL] [Abstract][Full Text] [Related]
26. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
Shen JS; Arning E; West ML; Day TS; Chen S; Meng XL; Forni S; McNeill N; Goker-Alpan O; Wang X; Ashcraft P; Moore DF; Cheng SH; Schiffmann R; Bottiglieri T
Hum Mol Genet; 2017 Mar; 26(6):1182-1192. PubMed ID: 28158561
[TBL] [Abstract][Full Text] [Related]
27. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
28. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
30. α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.
Miller JJ; Aoki K; Mascari CA; Beltrame AK; Sokumbi O; North PE; Tiemeyer M; Kriegel AJ; Dahms NM
FASEB J; 2019 Jan; 33(1):418-429. PubMed ID: 29979634
[TBL] [Abstract][Full Text] [Related]
31. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy.
Biancini GB; Jacques CE; Hammerschmidt T; de Souza HM; Donida B; Deon M; Vairo FP; Lourenço CM; Giugliani R; Vargas CR
Clin Chim Acta; 2016 Oct; 461():41-6. PubMed ID: 27458128
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease: where are we now?
Turkmen K; Baloglu I
Int Urol Nephrol; 2020 Nov; 52(11):2113-2122. PubMed ID: 32661622
[TBL] [Abstract][Full Text] [Related]
33. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
34. Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
Weidemann F; Sanchez-Niño MD; Politei J; Oliveira JP; Wanner C; Warnock DG; Ortiz A
Orphanet J Rare Dis; 2013 Aug; 8():116. PubMed ID: 23915644
[TBL] [Abstract][Full Text] [Related]
35. Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy.
Hongo K; Harada T; Fukuro E; Kobayashi M; Ohashi T; Eto Y
Mol Genet Metab Rep; 2020 Sep; 24():100623. PubMed ID: 32714835
[TBL] [Abstract][Full Text] [Related]
36. Progress in the understanding and treatment of Fabry disease.
Miller JJ; Kanack AJ; Dahms NM
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129437. PubMed ID: 31526868
[TBL] [Abstract][Full Text] [Related]
37. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.
Germain DP; Altarescu G; Barriales-Villa R; Mignani R; Pawlaczyk K; Pieruzzi F; Terryn W; Vujkovac B; Ortiz A
Mol Genet Metab; 2022; 137(1-2):49-61. PubMed ID: 35926321
[TBL] [Abstract][Full Text] [Related]
38. Renal complications of Fabry disease in children.
Najafian B; Mauer M; Hopkin RJ; Svarstad E
Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
[TBL] [Abstract][Full Text] [Related]
39. Cardiac involvement in Fabry disease - A non-invasive assessment and the role of specific therapies.
Hongo K
Mol Genet Metab; 2022; 137(1-2):179-186. PubMed ID: 36088815
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Daidone M; Miceli S; Pinto A
Curr Pharm Des; 2020; 26(40):5089-5099. PubMed ID: 32183665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
